AZITRA INC

AZTRNYSE AMERICAN

🏆 #4320 by market capUS Equity

$0.13▼ $0.01 (−5.48%)

Market closed · at close

1h—

24h▼ 5.5%

7d▼ 3.0%

14d▲ 3.3%

30d▲ 0.8%

1y▼ 86.4%

🏦Market Cap

$1M

Small Cap

📈Revenue Growth (YoY)

-100.0%

Declining

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $0.13 – $0.13
52-Week Range: $0.10 – $1.40
Volume: $2.16B
Avg Volume: $1.49B
Shares Outstanding: 10.7M
Next Earnings: Oct 11, 2026

Fundamentals Snapshot

Annual Revenue: $375,359
Last Q Revenue: $92,572
P/E Ratio: -0.1
P/S Ratio: 0.0x
EPS (TTM): $-0.76
Dividend Yield: 0.00%

Why Investors Own AZTR

✓High-growth profile — revenue up -6.3% YoY with expanding US Equity exposure.
✓Healthy economics — 46% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$375,359▼ −9.7% YoY

Gross Margin (TTM)

45.6%▼ −0.5% YoY

Operating Income (TTM)

$55,929▼ −9.7% YoY

Free Cash Flow (TTM)

$27,026▼ −9.7% YoY

About AZITRA INC

Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.

🦦